Abstract
The treatment of choice for limited small-cell lung cancer (SCLC) is platinum-based chemotherapy combined with early, concurrent thoracic radiotherapy with a hyperfractionated regimen. The standard chemotherapy for extensive SCLC in Japan is the combination of irinotecan and cisplatin. There are expectations for new and effective molecular-target-based drugs for SCLC.
MeSH terms
-
Anthracyclines / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Camptothecin / administration & dosage
-
Camptothecin / analogs & derivatives*
-
Carcinoma, Small Cell / drug therapy*
-
Carcinoma, Small Cell / radiotherapy*
-
Cisplatin / administration & dosage
-
Combined Modality Therapy
-
Dose Fractionation, Radiation
-
Drug Administration Schedule
-
Etoposide / administration & dosage
-
Humans
-
Irinotecan
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / radiotherapy*
-
Survival Analysis
Substances
-
Anthracyclines
-
Etoposide
-
Irinotecan
-
amrubicin
-
Cisplatin
-
Camptothecin